COMPARISON
Lixisenatide vs Tirzepatide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Lixisenatide is authorised or registered in 8 and Tirzepatide in 10 of the 10 registers read. Lixisenatide: No trial states a phase. Tirzepatide: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Lixisenatide | Tirzepatide | |
|---|---|---|
| Registered trials differs | 75 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Soliqua 100/33 openfda · 2026-10-03T17:23:44.062Z | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2017-01-11 ema · 2026-10-03 | 2022-09-15 ema · 2026-10-03 |
| EU withdrawn on differs | 2024-08-27 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for tirzepatide |
| ATC code differs | A10AE54 ema · 2026-10-03 | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Lixisenatide | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| Nausea | 24.8% | 6.5% | 25.6% | 8.1% |
| Vomiting | 10.3% | 2.6% | 11.4% | 2.6% |
| Diarrhoea | 10.1% | 8.1% | 21.2% | 8.3% |
| Headache | 9.6% | 6.8% | 6.6% | 6.2% |
| Hypoglycaemia | 18.4% | 16.4% | - | - |
| Nasopharyngitis | 9.1% | 9.0% | - | - |
| Dizziness | 8.3% | 6.3% | - | - |
| Hypertension | 4.6% | 4.9% | - | - |
| Influenza | 4.4% | 2.4% | - | - |
| Angina pectoris | 4.3% | 5.5% | - | - |
| Covid-19 | - | - | 15.5% | 16.0% |
| Constipation | - | - | 13.7% | 4.5% |
| Decreased appetite | - | - | 11.6% | 2.9% |
| Dyspepsia | - | - | 7.9% | 2.7% |
| Abdominal pain | - | - | 6.0% | 2.7% |
| Upper respiratory tract infection | - | - | 5.7% | 6.2% |
Trial register Lixisenatide: 11 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lixisenatide side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Lixisenatide | Tirzepatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.